OBJECTIVE: We explored the hypothesis that marked decline in plasma zinc concentrations among critically ill children is related to shifts in metallothionein expression and inflammation. DESIGN: Prospective pilot study. SETTING: Intensive care unit of tertiary care children's hospital. PATIENTS: All children (<18 yrs) with unadjusted Pediatric Risk of Mortality III score >5 or at least one organ failure admitted to the pediatric intensive care unit from March through August 2006 were eligible for enrollment. INTERVENTIONS: After consent, blood samples were collected on days 1 and 3 of illness and analyzed for serum chemistries, plasma zinc and copper levels, metallothionein isoform expression, and cytokine levels. MEASUREMENTS AND MAIN RESULTS: Twenty patients were enrolled, with median age of 2.9 yrs (interquartile range, 0.7-10.1). Male to female ratio was 1.2:1. All patients had low zinc levels (mean, 0.43; range, 0.26-0.66 mug/dL) on day 1 of pediatric intensive care unit admission, and remained low (mean, 0.51; range, 0.26-0.81 mug/dL) on day 3, even when corrected for hypoalbuminemia. In comparison, serum copper levels were normal. On day 1, there was a positive correlation between zinc levels and expression of MT-1A (p < 0.01), MT-1G (p = 0.02), and MT-1H (p = 0.03). Plasma zinc levels correlated inversely with C-reactive protein levels (r = -.75, p = 0.01) and interleukin-6 levels (r = -.53, p = 0.04) on day 3. On day 3, patients with two or more organ failures had significantly lower plasma zinc concentrations compared with patients with </=1 organ failure (p = 0.03). CONCLUSIONS: Plasma zinc concentrations are low in critically ill children. Plasma zinc correlated with measures of inflammation (C-reactive protein and interleukin-6) on day 3; low plasma zinc concentrations were associated with the degree of organ failure on day 3. These data serve as the basis for a larger study of shifts in plasma zinc concentrations in critically children to potentially identify patients who might benefit from zinc supplementation.
OBJECTIVE: We explored the hypothesis that marked decline in plasma zinc concentrations among critically ill children is related to shifts in metallothionein expression and inflammation. DESIGN: Prospective pilot study. SETTING: Intensive care unit of tertiary care children's hospital. PATIENTS: All children (<18 yrs) with unadjusted Pediatric Risk of Mortality III score >5 or at least one organ failure admitted to the pediatric intensive care unit from March through August 2006 were eligible for enrollment. INTERVENTIONS: After consent, blood samples were collected on days 1 and 3 of illness and analyzed for serum chemistries, plasma zinc and copper levels, metallothionein isoform expression, and cytokine levels. MEASUREMENTS AND MAIN RESULTS: Twenty patients were enrolled, with median age of 2.9 yrs (interquartile range, 0.7-10.1). Male to female ratio was 1.2:1. All patients had low zinc levels (mean, 0.43; range, 0.26-0.66 mug/dL) on day 1 of pediatric intensive care unit admission, and remained low (mean, 0.51; range, 0.26-0.81 mug/dL) on day 3, even when corrected for hypoalbuminemia. In comparison, serum copper levels were normal. On day 1, there was a positive correlation between zinc levels and expression of MT-1A (p < 0.01), MT-1G (p = 0.02), and MT-1H (p = 0.03). Plasma zinc levels correlated inversely with C-reactive protein levels (r = -.75, p = 0.01) and interleukin-6 levels (r = -.53, p = 0.04) on day 3. On day 3, patients with two or more organ failures had significantly lower plasma zinc concentrations compared with patients with </=1 organ failure (p = 0.03). CONCLUSIONS: Plasma zinc concentrations are low in critically ill children. Plasma zinc correlated with measures of inflammation (C-reactive protein and interleukin-6) on day 3; low plasma zinc concentrations were associated with the degree of organ failure on day 3. These data serve as the basis for a larger study of shifts in plasma zinc concentrations in critically children to potentially identify patients who might benefit from zinc supplementation.
Authors: Atta U Shahbaz; Tieqiang Zhao; Wenyuan Zhao; Patti L Johnson; Robert A Ahokas; Syamal K Bhattacharya; Yao Sun; Ivan C Gerling; Karl T Weber Journal: Am J Physiol Heart Circ Physiol Date: 2010-11-12 Impact factor: 4.733
Authors: Natalie Z Cvijanovich; Janet C King; Heidi R Flori; Ginny Gildengorin; Alexander A Vinks; Hector R Wong Journal: JPEN J Parenter Enteral Nutr Date: 2015-02-19 Impact factor: 4.016
Authors: Beth Y Besecker; Matthew C Exline; Jennifer Hollyfield; Gary Phillips; Robert A Disilvestro; Mark D Wewers; Daren L Knoell Journal: Am J Clin Nutr Date: 2011-04-27 Impact factor: 7.045
Authors: Siarhei Slinko; Giovanna Piraino; Paul W Hake; John R Ledford; Michael O'Connor; Patrick Lahni; Patrick D Solan; Hector R Wong; Basilia Zingarelli Journal: Shock Date: 2014-04 Impact factor: 3.454
Authors: Preetha Jothimuthu; Robert A Wilson; Josi Herren; Xing Pei; Wenjing Kang; Rodney Daniels; Hector Wong; Fred Beyette; William R Heineman; Ian Papautsky Journal: Electroanalysis Date: 2013-02 Impact factor: 3.223